Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SpringWorks Therapeutics Inc.

http://www.springworkstx.com

Latest From SpringWorks Therapeutics Inc.

Stock Watch: Cancer Combination Therapies Face Rising Bar

Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.

Stock Watch Companies

Oncternal And SpringWorks Among Early ASCO Winners And Losers

While the big pharma names dominate the ASCO cancer congress, it is also a chance to shine for emerging small-to-medium biopharma companies.

Cancer Companies

SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode

The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.

Cancer Clinical Trials

Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability

Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.

Clinical Trials ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • MapKure, LLC
    • SpringWorks Therapeutics, LLC
UsernamePublicRestriction

Register